Medical education company Pri-Med said on Tuesday that it has entered into a new partnership with the Brain Aneurysm Foundation (BAF) to deliver "Update in Diagnosis and Management of Intracranial Aneurysms for Primary Health Care Providers" at Pri-Med Midwest in Rosemont, IL on 10 October 2018.
During the medical session, Sepideh Amin-Hanjani, MD, University of Illinois at Chicago, will address how to recognise signs of an aneurysm rupture, when to make a referral and order appropriate imaging, and best practices for educating the patient about the risk factors for aneurysm formation and rupture.
According to the company, one in 50 people in the US has an unruptured brain aneurysm and 30,000 of them rupture every year. Despite low frequency, brain aneurysms are high in mortality, because the lack of a timely diagnosis often leads to death.
This session will focus on the importance of proper diagnosis and scanning and faculty will discuss treatment options to use in practice to meet the need for early detection of brain aneurysm.
Brain Aneurysm Foundation (BAF) is a non-profit organization dedicated to providing critical awareness, education, support, advocacy, and research funding to reduce the incidence of brain aneurysm ruptures.
AstraZeneca reports positive Phase III data for Imfinzi and Imjudo in liver cancer
Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development
Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal
NJ Bio and Aji Bio-Pharma partner to strengthen support for ADC development
Alltrna granted approval for first-in-human clinical trial of AP003
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management
AstraZeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia
Galapagos and Gilead expand collaboration to advance T cell engager programme
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics